reviewed the data. "The more effective of the two trial regimes, starting with half a dose, could provide advantages, according to Oxford Professor Andrew Pollard." Pollard said in a BBC radio interview, "It means we will have a lot more doses to distribute if that way of vaccinating was approved. Those who g